Abstract 209P
Background
Immune-cell indices of immunohistochemistry (IHC) are calculated in countless research studies; often to identify prognostic or predictive biomarkers in cancer patients. The study aimed to investigate how the location of immune cells and the amount of tumor epithelia may affect their calculation in breast cancer (BC) patients whilst exploring multiple sample techniques for IHC immune-cell quantification.
Methods
Formalin-fixed, paraffine-embedded pretreatment tumor tissue (N=227; full-cut slides) from BC patients was stained with two multiplexed chromogenic IHC using CK7/19, CD8, CD4, FOXP3, CD20, CD66b, and CD68. AI-powered image analysis (U-net) determined their area-based indices in the reference spaces: total tumor area, tumor stroma, tumor epithelia, a stromal tumor brim, and a fixed area for each lesion using multiple subsamples (mean no., 100) within tumor stroma (in total, 1 mm2) and epithelia (in total, 1 mm2).
Results
Immune cells were predominantly situated in tumor stroma and rarely epithelia (P<0.01). The most infiltrative cell type was CD68 with a mean index of 3% for epithelia, yet 32% for stroma. In remainder cells, indices were <0.7% for epithelia. The amount of epithelia ranged from 1-60%, which strongly affected index calculations that included the total area of epithelia (P<0.01). In addition, solidity of tumor islands was highly associated with the number of infiltrative CD8, CD66b, and CD68 cells (P<0.01).
Conclusions
The location (stroma vs epithelia) of each immune cell of interest should be considered in connection to its index calculation because the amount of tumor epithelia may skew the result. Alternatively, the novel, unbiased subsampling developed in this study could be used. High solidity meant fewer infiltrating cells, which, conceivably, may affect both prognostic and predictive utility of immune cells.
Legal entity responsible for the study
The authors.
Funding
Danish Cancer Society.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
137P - Hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study
Presenter: Jianbing Wu
Session: Poster Display session
138P - Interim results of neoadjuvant TACE plus lenvatinib and tislelizumab in resectable HCC at CNLC stages IB and IIA with high-risk of recurrence: A prospective, single-arm, phase II trial
Presenter: Yuhua Zhang
Session: Poster Display session
139P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display session
140P - Tislelizumab combined with lenvatinib and transarterial chemoembolization(TACE) neoadjuvant treatment in resectable CNLC IIa-IIb hepatocellular carcinoma: A prospective, single-arm, phase II study
Presenter: Zhibo Zhang
Session: Poster Display session
141P - Efficacy and safety of tislelizumab(T) combined with gemcitabine and cisplatin(GC) for patients with localized muscle-invasive bladder cancer(MIBC) after radical local surgery: A prospective, phase II study
Presenter: Ming Cao
Session: Poster Display session
Resources:
Abstract
143P - Strength of patient (pt) preference for atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) for the treatment of NSCLC: exploratory analyses from the IMscin002 study
Presenter: Margarita Majem Tarruella
Session: Poster Display session
144P - First-line cemiplimab monotherapy for advanced non-small cell lung cancer (NSCLC) of squamous histology: Subgroup analysis with 5-year results from EMPOWER-Lung 1
Presenter: Tamta Makharadze
Session: Poster Display session